Growth hormone secretagogue receptor 1a (GHSR1a)

Growth hormone secretagogue receptor 1a is a metabotropic G protein-coupled receptor that serves as the primary binding site for ghrelin—the endogenous “hunger” peptide—and other synthetic growth hormone-releasing peptides. It is predominantly expressed in the pituitary gland and various regions throughout the central nervous system. Upon activation by its ligands, it stimulates secretion—but not synthesis—of growth hormone from pituitary cells. The receptor exhibits constitutive activity even without ligand binding; this baseline signaling is important for normal physiological processes such as height development through its effect on the GH axis. Beyond regulating appetite and energy balance via hypothalamic circuits, it also modulates dopaminergic neurotransmission implicated in reward behaviors and addiction. Dysregulation or genetic variation within this pathway has been linked to conditions including obesity, short stature syndromes, neurodegenerative diseases like Alzheimer’s disease, substance use disorders/addiction behaviors, cancer cachexia/anorexia syndrome among others. Therapeutic strategies targeting this molecule include both agonist drugs aimed at stimulating GH release/appetite where needed (e.g., cachexia) and antagonists/inverse agonists designed to suppress excessive hunger/metabolic drive seen in obesity. Recent advances focus on developing biased ligands that selectively engage beneficial downstream pathways while avoiding adverse effects associated with global activation/inhibition of all signaling branches.

Other names

Ghrelin receptorGrowth hormone secretagogue receptor type 1aGHS-R1aGHSR

Agonists stimulate the receptor to promote growth hormone release via activation of downstream signaling cascades including MAPK, PKA, PKB/Akt, AMPK pathways. Inverse agonists suppress constitutive activity to reduce appetite/hunger signals or modulate metabolic effects. Biased ligands can selectively activate specific intracellular signaling branches to achieve desired therapeutic outcomes while minimizing side effects.